Breakthrough to develop ‘holy grail’ vaccine that protects against multiple variants of Covid

Researchers have made a “promising” breakthrough in the race to develop a “holy grail” vaccine that can protect against multiple resistance. I’m sick Variants and a variety of common colds caused by other coronaviruses.

Efforts to develop a so-called “pan-coronavirus vaccine” have so far been largely unsuccessful. This type of jab should remain effective in the face of frequent mutations.

But scientists at the Francis Crick Institute now believe they have identified a genetic feature of Sars-CoV-2 that appears to be “similar” to a number of coronaviruses and is less prone to mutations, making it a potential target for pan-CoV-2. Corona virus, i.e. universal vaccine.

In their study, published today Science Translational MedicineThe researchers investigated whether antibodies trained to target the S2 subunit of the Sars-CoV-2 protein could also neutralize other coronaviruses.

The S2 subunit binds the spike to the viral membrane and allows the virus to fuse with the host cell membrane.

When used in mice, the scientists’ vaccine produced antibodies that targeted the S2 subunit and could neutralize different types of coronaviruses, including the seasonal “common cold” coronavirus HCoV-0C43, the original strain of Sars-CoV-2. Alpha, Beta, Delta, the original Omicron variant and two bat coronaviruses.

Kevin Ng, one of the study’s co-authors and a postdoctoral fellow in the Francis Crick Institute’s Retrovirus Laboratory, said the S2 region of the spike protein was “a promising target for a potential pan-coronavirus vaccine because this region is much larger. Similar in different coronaviruses than the S1 zone. It is less susceptible to mutations and therefore a vaccine targeting this area should be more potent.

George Kassiotis, a key group leader at the Francis Crick Institute, said a vaccine specific to the S2 subunit could potentially provide protection against current and future coronaviruses.

“This is in contrast to vaccines that target a more variable S1 region that is effective against the variants they are designed against, less able to target other variants or a wider range of coronaviruses,” he added.

“There is still much research to be done as we continue to test the S2 antibody against different coronaviruses and look for the most suitable way to develop and test a potential vaccine.”

The S2-specific vaccine would not necessarily stop people from becoming infected – as the current range of Covid seems to be – but would try to “prime” an individual’s immune system to “respond to a future coronavirus infection”, the researchers said.

Earlier this year, the World Health Organization’s chief scientist said that “the development of a pan-coronavirus vaccine that can cover the different variants of Sars-CoV-2 and possibly extend to and be effective against other coronaviruses would be the Holy Grail.” .

Soumya Swaminathan told him British Medical Journal: “It seems scientifically quite plausible that it will develop over the next couple of years – this is partly due to the huge amount of research being done on Sars-CoV-2.”

Breakthrough to develop ‘holy grail’ vaccine that protects against multiple variants of Covid

Source link Breakthrough to develop ‘holy grail’ vaccine that protects against multiple variants of Covid

Back to top button